Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 5/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5051228 | 0.85 | TDP1 (0.46) | SLC6A3HPGDGAAKMT2AMEN1 | |
| SCHEMBL7604660 | 0.78 | SMN1; SMN2 (0.48) | SLC6A3HPGDGAAKMT2AMEN1 | |
| SCHEMBL5054724 | 0.76 | SLC6A3 (0.47) | SLC6A3HPGDGAAKMT2AMEN1 | |
| SCHEMBL5059792 | 0.76 | HPGD (0.45) | SLC6A3HPGDGAAKMT2AMEN1 | |
| SCHEMBL5051305 | 0.75 | HPGD (0.50) | HPGDGAAKMT2AMEN1TDP1 | |
| SCHEMBL5053050 | 0.74 | HPGD (0.40) | HPGDGAAKMT2AMEN1HTT | |
| SCHEMBL5053186 | 0.73 | ACP3 (0.41) | KMT2AMEN1ALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL5054585 | 0.73 | HPGD (0.48) | HPGDGAAKMT2AMEN1TDP1 | |
| SCHEMBL8061269 | 0.73 | HPGD (0.43) | SLC6A3HPGDGAAKMT2AMEN1 | |
| SCHEMBL7611227 | 0.72 | GGH (0.49) | HPGDKMT2AMEN1HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020151503-A1 | Methods of cancer treatment using naaladase inhibitors | SLUSHER BARBARA S (US) | 2002-10-17 | — | — | US | claimed |
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | claimed |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-12-18 | — | — | US | disclosed |
| WO-2006093991-A1 | COMPOUNDS WHICH BIND PSMA AND USES THEREOF | THE CLEVELAND CLINIC FOUNDATION (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | SLUSHER BARBARA S (US) | 2003-04-03 | — | — | US | disclosed |
| US-20020151503-A1 | Methods of cancer treatment using naaladase inhibitors | SLUSHER BARBARA S (US) | 2002-10-17 | — | — | US | disclosed |
| US-6413948-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-07-02 | — | — | US | disclosed |
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | disclosed |
| US-6384022-B1 | ENZYME INHIBITORS | GUILFORD PHARMACEUTICALS INC. | 2002-05-07 | — | — | US | disclosed |
| US-6372726-B1 | ADMINISTERING CARBOXYALKYL PHOSPHONATE, PHOSPHORAMIDATE, OR PHOSPHINE OXIDE DERIVATIVE AS ANTITUMOR AGENT TO TREAT CANCER OF PROSTATE GLAND | GUILFORD PHARMACEUTICALS INC. | 2002-04-16 | — | — | US | disclosed |
| US-6046180-A | NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. (US) | 2000-04-04 | — | — | US | disclosed |
| US-5977090-A | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | NAALAD2, DNPEP, DPP9 | SLC6A3 1996/4885HPGD 474/4885GAA 15/4885 |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | FOLH1, PSMA1, BPHL | SLC6A3 1060/4885HPGD 3806/4885GAA 77/4885 |
| US-20020151503-A1 | Methods of cancer treatment using naaladase inhibitors | NAALAD2, DNPEP, ACP3 | SLC6A3 1361/4885HPGD 423/4885GAA 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.